Molecular Docking and Dynamic Simulation of AZD3293 and Solanezumab Effects Against BACE1 to Treat Alzheimer's Disease

Molecular Docking and Dynamic Simulation of AZD3293 and Solanezumab Effects Against BACE1 to Treat Alzheimer's Disease

The design of novel inhibitors to target BACE1 with reduced cytotoxicity effects is a promising approach to treat Alzheimer's disease (AD). Multiple clinical drugs and antibodies such as AZD3293 and Solanezumab are being tested to investigate their therapeutical potential against AD. The curren...

Full description

Bibliographic Details
Main Authors: Mubashir Hassan, Saba Shahzadi, Sung Y. Seo, Hany Alashwal, Nazar Zaki, Ahmed A. Moustafa
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-06-01
Series:Frontiers in Computational Neuroscience
Subjects:
Alzheimer's disease
computational modeling
dynamic simulation
AZD3293
solanezumab
Online Access:https://www.frontiersin.org/article/10.3389/fncom.2018.00034/full

Internet

https://www.frontiersin.org/article/10.3389/fncom.2018.00034/full

Similar Items